耐受性
左乙拉西坦
医学
不利影响
癫痫
上市后监督
临床试验
重症监护医学
麻醉
药理学
内科学
精神科
作者
Santiago Arroyo,Pamela Crawford
出处
期刊:PubMed
日期:2003-05-01
卷期号:5 Suppl 1: S57-63
被引量:4
摘要
A good balance between safety and tolerability is necessary for an antiepileptic drug (AED) to be successful in the management of patients with epilepsy. Levetiracetam is one of the new generation of AEDs licensed as an add-on therapy for the treatment of patients with partial-onset seizures. Leveti-racetam's mechanisms of action are not fully understood. Controlled clinical trials, open-label studies, and postmarketing surveillance indicate that leveti-racetam has a favorable safety profile characterized by little effect on vital signs or clinical laboratory values, reported adverse events that are mild to moderate, and no known drug-drug interactions. The tolerability of levetiracetam may extend to both pediatric and elderly patients based on analyses of small numbers of patients. Tolerability is maintained over the long term. Levetirac-etam does not appear to have a different safety profile in learning-disabled patients. Levetiracetam appears to have a good balance between tolerability and efficacy in the treatment of a wide variety of patients with partial epilepsy.
科研通智能强力驱动
Strongly Powered by AbleSci AI